Skip to main
COGT

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is positioned for significant growth, particularly in 2025, which may enhance its attractiveness as a merger and acquisition target, driven by the potential success of its key programs APEX and PEAK. The company's probability of approval for bezuclastinib in the second-line gastrointestinal stromal tumors (GIST) has been raised to 90%, indicating a strong likelihood of market entry, while peak penetration rates have also been substantially increased to 35%. Moreover, positive data from the APEX, PEAK, and SUMMIT trials underscore bezuclastinib's potential impact across various malignancies, reinforcing confidence in the company's long-term prospects.

Bears say

Cogent Biosciences is projected to incur a significant net loss of $2.28 per share for the full year 2025, indicating ongoing financial challenges. The company faces multiple risks, including potential negative clinical data, slower-than-expected development timelines, and significant hurdles in obtaining regulatory approvals for its therapies. Additionally, setbacks in both later-stage and earlier-stage clinical trials contribute to concerns over lower-than-expected commercial success and the risk of long-term dilution, raising red flags regarding the company's future financial viability.

Cogint (COGT) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 10 analysts, Cogint (COGT) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.